Europe Sepsis Diagnostics Market

Europe Sepsis Diagnostics Market Size

The Europe Sepsis Diagnostics Market was valued at USD 466.93 million in 2024, is expected to have an 8.43% CAGR from 2025 to 2033 and be worth USD 967.38 million by 2033 from USD 506.29 million in 2025.

Sepsis diagnostics include medical technologies and assays designed to rapidly identify the presence of infection, systemic inflammation, and organ dysfunction indicative of sepsis, which is a life-threatening condition triggered by the body’s dysregulated response to pathogens. These diagnostics include blood culture systems molecular assays, biomarker tests such as procalcitonin, interleukin 6 and presepsi, as well as emergency point-of-care and multiplex platforms that enable pathogen identification and antimicrobial susceptibility profiling. Timely and accurate diagnosis is critical, as sepsis mortality increases by approximately 8% for every hour antimicrobial therapy is delayed, according to the European Society of Intensive Care Medicine. Sepsis affects millions of people annually in the European Union, resulting in hundreds of thousands of deaths each year. The condition places immense strain on healthcare systems, with the average ICU stay for septic patients commonly exceeding one week. With the growing aging populations, rising antimicrobial resistance, and institutional protocols emphasizing early recognition, sepsis diagnostics have become a cornerstone of critical and emergency care. Regulatory frameworks under the EU In Vitro Diagnostic Regulation 2017/746 now mandate enhanced clinical evidence for sepsis tests, ensuring analytical validity and clinical utility. This evolving landscape positions diagnostics not merely as laboratory tools but as pivotal components of time‑sensitive sepsis bundles endorsed across European hospitals.

MARKET DRIVERS

High sepsis incidence and an aging population are driving clinical urgency.

The rising burden of sepsis across Europe is a primary driver of diagnostic demand. According to the European Sepsis Alliance, more than 2.8 million people in Europe survive sepsis annually, yet every minute one person dies from the condition. This translates to millions of new cases each year, which indicates the scale of clinical urgency. As per Eurostat, 21.6% of the EU population was aged 65 or older in 2024, a cohort at significantly elevated risk due to immunosenescence, comorbidities, and frequent healthcare exposure. According to the European Centre for Disease Prevention and Control (ECDC), older adults represent the majority of sepsis hospitalizations, with mortality rates exceeding 30% in this group. Furthermore, chronic conditions such as diabetes, cancer, and renal failure affect over 25% of Europeans above 60 according to the OECD Health at a Glance Europe 2024 report, further predisposing individuals to severe infections. National sepsis action plans in Germany, the UK, and Sweden mandate screening for emergency admissions over 60, which is directly increasing utilization of biomarkers such as procalcitonin and lactate. The convergence of epidemiological pressure and institutionalized early recognition protocols ensures sustained demand for rapid sepsis diagnostics, justifying high incidence and aging demographics as a structural growth driver.

Regulatory push for early recognition and standardized sepsis protocols

The expansion of mandatory sepsis screening across European healthcare systems further expands the European sepsis diagnostics market. According to the European Society of Intensive Care Medicine (ESICM), hour-one bundles such as “Sepsis Six” require lactate and biomarker measurement within the first hour of suspected sepsis. In 2023, the UK National Health Service (NHS) made sepsis screening compulsory in all acute trusts, which links compliance to hospital funding and public reporting. Similarly, Germany’s Federal Joint Committee (G-BA) approved new sepsis quality indicators to be implemented nationwide from 2026, including detection time as a reimbursable metric. As per the European Observatory on Health Systems and Policies, at least 17 EU member states now have national sepsis strategies referencing diagnostic biomarkers as essential components of early intervention. The European Commission’s Patient Safety Initiative further supports integration of sepsis diagnostics into electronic health records with automated alerts for abnormal vital signs and lactate levels. These institutional frameworks transform sepsis diagnostics from optional tools into mandated workflow elements, which ensure consistent utilization across public and private healthcare. By embedding diagnostics into national quality mandates, Europe guarantees sustained procurement and adoption, justifying regulation as a decisive driver of market growth.

MARKET RESTRAINTS

High Cost and Reimbursement Limitations for Advanced Diagnostics

The adoption of advanced sepsis diagnostics in Europe is restrained by limited reimbursement coverage and high out‑of‑pocket costs. According to the European Diagnostic Manufacturers Association (EDMA), fewer than 10 EU countries provide full reimbursement for multiplex sepsis panels, with average patient co‑payments exceeding €200 in France, Italy, and Spain. This restricts access to molecular assays and multiplex PCR platforms outside tertiary hospitals. As per the German Institute for Quality and Efficiency in Health Care (IQWiG 2023), rapid molecular tests reduce time to pathogen identification by up to 36 hours, yet their incremental cost per quality‑adjusted life year exceeds €50,000, limiting cost‑effectiveness approval. In Eastern Europe, reimbursement remains more restrictive as the Polish Ministry of Health covers only blood culture and lactate testing under its basic benefit package, which leaves advanced diagnostics largely unavailable. The European Centre for Disease Prevention and Control (ECDC) reports that 60% of sepsis cases originate in community hospitals, where financial barriers delay access to precise diagnostics. These limitations suppress equitable adoption, slow market penetration, and justify reimbursement gaps as a structural restraint on growth.

Fragmented Adoption of Diagnostic Guidelines Across Member States

The lack of harmonized clinical guidelines and variable implementation of sepsis protocols across European countries is a major challenge that hinders consistent demand for standardized diagnostic tools. According to the European Observatory on Health Systems and Policies (2024), only 12 EU member states have fully integrated biomarker testing into national treatment algorithms, which directly limits uniform uptake of advanced diagnostics. As per a European Society of Clinical Microbiology and Infectious Diseases (ESCMID) survey (2024), only 35% of hospitals in Romania, Bulgaria, and Greece routinely measure procalcitonin compared to over 85% in Germany and the Netherlands, highlighting significant regional disparities. According to the World Health Organization (WHO Europe), per capita spending on laboratory services in low‑income EU states is less than one third of that in Western Europe, which constrains infrastructure and training capacity. These disparities force diagnostic companies to navigate fragmented markets where regulatory approval does not guarantee clinical use. Without coordinated EU‑level action to standardize sepsis care pathways, innovation risks benefiting only high‑resource regions. This uneven adoption justifies fragmented guidelines as a critical challenge that undermines equitable patient outcomes and slows market scalability.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence with Diagnostic Platforms

The convergence of artificial intelligence (AI) and sepsis diagnostics is a promising opportunity for the European sepsis diagnostics market. According to the European Society of Intensive Care Medicine (ESICM), AI‑driven early warning systems can reduce sepsis mortality by up to 22% through timely intervention, which directly improves patient survival and accelerates adoption. In 2024, the French National Authority for Health (HAS) approved an AI algorithm combining procalcitonin, lactate, and inflammatory markers to predict septic shock with 91% sensitivity, which demonstrates regulatory confidence in AI‑enabled diagnostics. Similarly, Germany’s University Hospital Heidelberg implemented a machine learning model that flagged at‑risk patients in emergency departments, which is reducing time to antibiotics by 58 minutes on average, highlighting a measurable clinical impact. The European Commission’s Horizon Europe programme allocated €40 million in 2024 to fund AI diagnostic validation studies, including sepsis prediction tools, which accelerate innovation pipelines. Device manufacturers are embedding interoperable algorithms into point‑of‑care analyzers, enabling seamless integration with hospital command centres. This fusion of diagnostics and digital intelligence positions sepsis detection as proactive rather than reactive and justifies AI integration as a high‑conviction opportunity for market expansion.

Expansion of Point of Care Testing in Community and Prehospital Settings

The decentralization of sepsis care is creating significant opportunities for point‑of‑care (POC) diagnostics. According to the European Centre for Disease Prevention and Control (ECDC), 60 percent of sepsis cases originate in the community, which underscores the importance of early detection outside tertiary hospitals. POC procalcitonin and lactate analyzers now deliver results in under 15 minutes, enabling paramedics and primary care physicians to initiate sepsis protocols before hospital arrival, which directly reduces delays in treatment. In Sweden, the national ambulance service equipped all emergency vehicles with handheld lactate meters in 2023, which reduced hospital sepsis recognition time by 70 percent, demonstrating measurable efficiency gains. The UK National Institute for Health and Care Excellence (NICE) updated its 2024 guidelines to recommend POC biomarker testing in primary care for patients with suspected infection and red‑flag symptoms, which formalizes adoption across frontline settings. Additionally, the European Commission’s Digital Europe Programme supports the integration of these devices into telehealth networks and allows remote specialist consultation. These portable tools bridge critical gaps in the care continuum, which is transforming community settings into active nodes of early detection and intervention. This decentralization justifies POC expansion as a structural opportunity for market growth.

MARKET CHALLENGES

Limited Clinical Validation of Novel Biomarkers in Diverse Populations

Insufficient validation of novel biomarkers across Europe’s heterogeneous patient populations is a major challenge for the European sepsis diagnostics market. According to the European Medicines Agency (EMA), over 60 percent of diagnostic studies submitted for CE marking under the In Vitro Diagnostic Regulation rely on single‑centre data from Western European hospitals, which limits generalizability. According to a 2024 multicentre study published in The Lancet Regional Health Europe, the sensitivity of presepsin dropped from 88% in young adults to 61% in patients over 75 with renal impairment, which highlights reduced performance in high‑risk cohorts. Similarly, as per the European Society of Clinical Microbiology (ESCMID), inconsistent interleukin‑6 cutoff values in diabetic versus non‑diabetic cohorts complicate clinical interpretation. These gaps risk misclassification, delayed treatment, and reduced clinician trust. Without large‑scale prospective validation across diverse settings, novel biomarkers will struggle to gain routine use. This lack of inclusive evidence justifies limited validation as a critical challenge that constrains innovation scalability.

Workforce Shortages and Lack of Training in Diagnostic Interpretation

A critical bottleneck in effective sepsis diagnostics is the shortage of trained staff capable of interpreting complex test results. According to the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), over 30% of EU countries face acute shortages of clinical microbiologists, with Eastern member states reporting vacancy rates exceeding 40%, which directly delays blood culture processing and antimicrobial susceptibility reporting. As per a 2024 survey by the European Society of Intensive Care Medicine (ESICM), only 45% of emergency physicians in Italy and Spain correctly interpreted procalcitonin levels in simulated sepsis cases, which indicates training gaps in biomarker‑guided decision making. The World Health Organization’s European Health Workforce Report (2024) identifies diagnostic stewardship as a key gap in sepsis management curricula, which limits integration of advanced tools into frontline care. In rural hospitals, reliance on basic diagnostics persists despite the availability of advanced assays, which further widens disparities. Without coordinated investment in workforce capacity and continuing medical education, the full potential of advanced sepsis diagnostics cannot be realized. This shortage justifies workforce gaps as a material challenge that constrains both clinical impact and market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Pathogen Insights

The bacterial sepsis segment dominated the European sepsis diagnostics market by holding 78.2% of the market in 2024. The dominance of the bacterial sepsis segment in this European market is attributed to its high clinical prevalence and established diagnostic protocols across acute care. According to the European Centre for Disease Prevention and Control, bacterial pathogens such as Escherichia coli and Klebsiella pneumoniae constitute a significant share of bloodstream infections in EU hospitals, necessitating routine blood cultures and rapid identification. As per the European Antimicrobial Resistance Surveillance Network, resistance to third‑generation cephalosporins among invasive E. coli isolates remains a critical stewardship concern, reinforcing demand for timely susceptibility testing. According to national sepsis guidance frameworks in Germany, the UK, and Sweden, blood cultures and biomarkers are recommended within the first hour of suspected sepsis to reduce morbidity. As per the European Society of Clinical Microbiology and Infectious Diseases, procalcitonin use supports differentiation of bacterial from non‑bacterial etiologies to curb unnecessary antibiotics. This segment is expected to remain dominant over the forecast period as incidence patterns, resistance pressures, and mandated early diagnostics sustain market demand.

The fungal sepsis segment is anticipated to grow at a promising CAGR of 9.3% over the forecast period in the European market. The rising burden in immunocompromised populations and greater ICU awareness are supporting the growth of the fungal sepsis segment in this European market. According to the European Centre for Disease Prevention and Control, invasive candidiasis and aspergillosis are increasingly recognized in intensive care cohorts, prompting expanded screening. As per the European Organization for Research and Treatment of Cancer, oncology and transplant patients remain at elevated risk for invasive fungal disease, necessitating earlier detection. According to the European Society of Clinical Microbiology and Infectious Diseases, β‑D‑glucan and galactomannan testing are recommended in high‑risk ICU patients to expedite antifungal decisions. As per major university hospital protocols in Germany and France, fungal biomarker panels are integrated into sepsis bundles for oncology ICUs. This segment is expected to expand rapidly over the forecast period as guideline adoption and direct‑from‑blood detection technologies broaden clinical use.

By Product Insights

The assay kits and reagents segment led the market and accounted for 42.4% of the European market share in 2024, owing to their indispensable role in biomarker and pathogen testing workflows. According to the European Federation of Clinical Chemistry and Laboratory Medicine, procalcitonin, C‑reactive protein, and interleukin‑6 assays are widely utilized across EU hospitals in suspected sepsis presentations. As per the European Society of Intensive Care Medicine, hour‑one sepsis bundles include biomarker testing to support risk stratification and stewardship, ensuring recurring consumable demand. According to national procurement authorities in France and Italy, centralized tenders for assay kits help maintain supply continuity and standardize test quality. As per large tertiary lab networks, the shift from manual ELISA to automated chemiluminescent platforms has increased per‑test reagent complexity and throughput. This segment is expected to remain dominant over the forecast period as protocol‑embedded consumables underpin routine diagnostics across care settings.

The software segment is anticipated to exhibit a CAGR of 11.2% over the forecast period in the European market. The integration of artificial intelligence and interoperable decision support is favouring the growth of the software segment in this European market. According to the European Health Telematics Observatory, tertiary hospitals in Germany, the Netherlands, and Sweden have deployed predictive sepsis tools that generate earlier clinical alerts from EHR and vital streams. As per the European Commission’s Digital Europe Programme, funded initiatives are advancing FHIR‑compliant sepsis alerting and hospital interoperability. According to the UK National Health Service Patient Safety Strategy, digital sepsis screening is being mandated across acute trusts to standardize early recognition. As per ICU telemedicine programs, software enables remote monitoring of biomarker trajectories and antimicrobial response to guide escalation. This segment is expected to expand steadily over the forecast period as subscription models, analytics performance, and regulatory endorsement deepen adoption.

By Technology Insights

The immunoassays segment occupied 36.3% of the European sepsis diagnostics market share in 2024. The leading position of the immunoassays segment in this European market is attributed to rapid quantification of protein biomarkers and compatibility with automated analyzers. According to the European Society of Intensive Care Medicine, procalcitonin immunoassays are widely used to guide initiation and duration of antibiotics under stewardship protocols. As per statutory reimbursement systems in Germany and France, immunoassay testing for suspected sepsis is covered, ensuring equitable access and routine use. According to the European Commission’s In Vitro Diagnostic Regulation, performance and traceability standards have harmonized analytical reliability across platforms. As per high‑throughput hospital laboratories, chemiluminescent immunoassay systems can process large emergency surges with short turnaround times. This segment is expected to remain dominant over the forecast period as clinical validation, coverage, and operational efficiency sustain front‑line utilization.

The molecular diagnostics segment is expected to register the fastest CAGR of 10.5% over the forecast period in the European market. The need for rapid pathogen identification and resistance gene profiling is propelling the growth of the molecular diagnostics segment in this European market. According to the European Antimicrobial Resistance Surveillance Network, multidrug‑resistant organisms represent a substantial share of severe infections, intensifying demand for precise molecular guidance. As per the European Society of Clinical Microbiology and Infectious Diseases, multiplex PCR or sequencing is advised in ICU cases with unclear sources to accelerate targeted therapy. According to German statutory health insurance decisions, reimbursement pathways for multiplex sepsis panels have been established following health technology assessments demonstrating clinical benefits. As per hospital emergency pathways in the Netherlands and Sweden, molecular platforms have been integrated to shorten the time to appropriate antibiotics. This segment is expected to expand robustly over the forecast period as turnaround times improve and costs decline.

By Usability Insights

The laboratory testing segment held the leading position in the European sepsis diagnostics market in 2024 and occupied 68.1% of the regional market share. The dominance of the laboratory testing segment in this European market is driven by core lab capacity for complex assays, microbiology expertise, and comprehensive susceptibility workups. According to the European Federation of Clinical Chemistry and Laboratory Medicine, most procalcitonin and blood culture testing in Western Europe is conducted in accredited hospital laboratories. As per national quality frameworks, including Germany’s RiliBÄK and the UK’s Clinical Pathology Accreditation, strict validation ensures reliable results for high‑risk indications such as sepsis. According to the European Commission’s In Vitro Diagnostic Regulation, high‑risk diagnostics require rigorous performance verification that is typically centralized. As per infection control reporting requirements, lab‑based testing supports surveillance and antimicrobial stewardship across hospital networks. This segment is expected to remain dominant over the forecast period as centralized expertise and instrumentation continue to anchor definitive diagnosis.

The point‑of‑care testing segment is expected to register the fastest CAGR of 12.1% over the forecast period in the European market. The imperative for immediate triage in emergency departments, ambulances, and primary care is propelling the growth of the point‑of‑care testing segment in this European market. According to the European Centre for Disease Prevention and Control, a substantial share of suspected sepsis presentations occurs outside ICUs, necessitating rapid initial testing. As per national emergency medical services programs, ambulance deployment of lactate meters has improved prehospital recognition times and early bundle activation. According to the UK’s National Institute for Health and Care Excellence, point‑of‑care biomarkers are recommended in specific primary care scenarios to accelerate referral. As per the European Commission’s Action Plan on Antimicrobial Resistance, decentralized diagnostics are encouraged to reduce empirical antibiotic use and improve targeting. This segment is expected to grow rapidly over the forecast period as connected and affordable devices extend sepsis detection across the care continuum.

COUNTRY LEVEL ANALYSIS

Germany Sepsis Diagnostics Market Analysis

In 2024, Germany stood out as the largest national market by holding 20.3% the European sepsis diagnostics market share due to its advanced hospital infrastructure, high ICU capacity, and stringent sepsis quality mandates tied to reimbursement. According to the Federal Office for Information Security, critical infrastructure hospitals conduct regular OT‑aligned clinical safety assessments that include sepsis pathway controls. As per the German Hospital Federation, Germany maintains one of Europe’s highest ICU capacities, which supports rapid diagnostics such as procalcitonin and early blood cultures. According to the Joint Federal Committee, reimbursement updates in 2023 recognized sepsis biomarker panels and rapid molecular tests to improve early recognition. As per the Paul Ehrlich Institute, leading university hospitals in Berlin, Munich, and Heidelberg are routinely involved in validation studies for novel sepsis diagnostics under national oversight. Germany is expected to remain Europe’s most sophisticated, high‑volume sepsis diagnostics market over the next few years.

France Sepsis Diagnostics Market Analysis

France accounted for the second-largest share of the European sepsis diagnostics market in 2024, owing to the centralized planning, strong lab networks, and proactive national surveillance and guidance. According to the French National Authority for Health, national sepsis guidance emphasizes early biomarker testing in emergency settings to standardize triage and treatment initiation. As per Santé publique France, sepsis surveillance is coordinated nationally, with community and hospital reporting used to inform diagnostic procurement and deployment. According to the Ministry of Health, targeted funding has been allocated to digital early‑warning systems and point‑of‑care expansion in public hospitals. As per the French Society of Infectious Diseases, oncology ICUs follow fungal diagnostics recommendations (including β‑D‑glucan use) to improve outcomes in high‑risk cohorts. France is expected to sustain a high‑adoption profile with strong policy leadership and equitable access in the coming years.

United Kingdom Sepsis Diagnostics Market Analysis

The United Kingdom is predicted to represent a prominent share of the European sepsis diagnostics market over the forecast period. Factors such as mandatory national protocols, digital integration, and strong patient‑safety governance are propelling the French market growth. According to NHS England, national sepsis improvement programs support electronic screening and biomarker use across acute trusts, with performance linked to oversight frameworks. As per the UK Health Security Agency, real‑time surveillance of pathogens and resistance trends informs diagnostic adoption and procurement for hospitals and ambulance services. According to NICE guidance updates, procalcitonin and lactate testing are incorporated within sepsis pathways to improve early recognition and antibiotic stewardship. As per the Medicines and Healthcare products Regulatory Agency, continued alignment with IVDR ensures access to advanced diagnostics post‑Brexit. The UK is expected to remain a high‑compliance, digitally integrated market over the next few years.

Italy Sepsis Diagnostics Market Analysis

Italy is estimated to exhibit a healthy CAGR in the European sepsis diagnostics market over the forecast period, owing to the regional disparities, rising antimicrobial resistance, and post‑pandemic modernization of critical care. According to the Italian National Institute of Health, national data showed a substantial sepsis burden with structured pathways expanding across regions to reduce delays in diagnosis. As per the Ministry of Health’s National Sepsis Plan 2023–2027, funding supports universal access to key biomarkers (including procalcitonin) and rapid molecular panels in ICUs. According to the European Antimicrobial Resistance Surveillance Network, Italy continues to face high levels of carbapenem‑resistant Enterobacterales, intensifying demand for resistance detection diagnostics. As per regional program updates, Northern regions such as Lombardy and Emilia‑Romagna lead adoption with integrated lab and point‑of‑care networks, while Southern regions accelerate through EU cohesion funds. Italy is expected to evolve rapidly into a high‑potential market with increasing standardization over the next few years.

Netherlands Sepsis Diagnostics Market Analysis

The Netherlands is anticipated to account for a notable share of the European sepsis diagnostics market during the forecast period owing to integrated care models, high laboratory automation, and stewardship‑led diagnostic pathways. According to the Dutch Working Party on Antibiotic Policy, procalcitonin‑guided therapy features in national recommendations for respiratory infections and sepsis and is widely adopted across hospitals. As per the National Institute for Public Health and the Environment, centralized microbiology networks support high‑throughput blood culture processing and rapid reporting integrated with electronic health records. According to the Dutch Healthcare Authority, reimbursement frameworks cover multiplex PCR diagnostics for ICU cases of unknown origin when cost‑effectiveness is demonstrated. As per the university hospital consortia, AI‑enabled sepsis alerts are being implemented to reduce time to antibiotics and standardize early recognition. The Netherlands is expected to remain a high‑efficiency, high‑value market, shaping best practices across Europe in the next few years. Sources (Netherlands): SWAB/Dutch Working Party on Antibiotic Policy; RIVM; Dutch Healthcare Authority (NZa); University hospital consortia

COMPETITIVE LANDSCAPE

The European sepsis diagnostics market features intense competition among global diagnostics leaders and specialized innovators vying for integration into time-critical clinical pathways. Competition is defined not by price but by analytical performance, speed of result, clinical validity, and compatibility with hospital digital ecosystems. Established players leverage extensive installed bases, automated platforms, and global regulatory expertise to dominate high-volume laboratory testing, while agile biotech firms gain traction with novel biomarkers and rapid molecular panels. The EU In Vitro Diagnostic Regulation has raised evidence requirements, creating barriers for smaller entrants but rewarding companies with robust clinical data. National sepsis protocols and antimicrobial stewardship programs act as key adoption accelerators with reimbursement tied to guideline compliance. Differentiation increasingly hinges on software intelligence, real-world evidence and support for decentralized testing. As sepsis care becomes more protocolized and digital, the market rewards those who offer end-to-end solutions spanning lab point of care and data analytics within a framework of clinical credibility and regulatory rigour.

KEY MARKET PLAYERS

Some of the major players in the europe sepsis diagnostics market include

• BioMérieux SA
• T2 Biosystem Inc
• Cepheid
• Thermo Fisher Scientific Inc.
• Nanosphere Inc
• Abbott Laboratories
• Roche Diagnostics Limited
• Becton, Dickinson and Company
• Bruker Corporation
• Beckman Coulter, Inc.

TOP LEADING PLAYERS IN THE MARKET

• bioMérieux S.A., a French multinational, is a global leader in sepsis diagnostics with deep integration in the European market through its comprehensive portfolio of blood culture systems, rapid molecular assays and biomarker tests. The company’s VITEK and BacT/ALERT platforms are widely used across EU hospitals for pathogen identification and antimicrobial susceptibility testing. bioMérieux actively contributes to global sepsis guidelines through partnerships with the World Health Organization and the European Society of Clinical Microbiology. In 2024, the company launched an upgraded SepsiTest Plus panel capable of detecting over 100 pathogens and 30 resistance genes directly from whole blood within five hours. It also expanded its procalcitonin immunoassay availability on automated platforms across Southern and Eastern Europe, reinforcing its position as a full solution provider aligned with antimicrobial stewardship goals.
• Thermo Fisher Scientific Inc. plays a pivotal role in the European sepsis diagnostics landscape through its advanced molecular and immunoassay technologies, including the QIAstat Dx and BRAHMS biomarker platforms. The company supplies reagents, instruments, and software that support rapid sepsis detection in both central laboratory and point-of-care settings across Western and Nordic countries. Thermo Fisher’s acquisition of Qiagen strengthened its infectious disease portfolio, enabling seamless integration of sample to result workflows. In early 202,4, the company received CE marking for the next-generation sepsis panel that identifies multidrug-resistant organisms and fungal pathogens using multiplex PCR. It also partnered with university hospitals in Germany and the Netherlands to validate AI-driven interpretation algorithms, enhancing clinical utility and speeding adoption in high acuity environments.
• Siemens Healthineers AG significantly influences the European sepsis diagnostics market through its Atellica and Dimension platforms, which deliver high-throughput procalcitonin and inflammatory marker testing integrated into hospital laboratory networks. The company’s focus on automation, connectivity, and electronic health record interoperability aligns with Europe’s digital health transformation. Siemens Healthineers provides end-to-end diagnostic solutions, including reagents, software, and service support, to over 1,200 hospitals across the EU. In 2024, it enhanced its Atellica VTL software to include real-time sepsis risk scoring by combining biomarker data with clinical parameters. The company also collaborated with the German Society of Sepsis to develop training modules for laboratory professionals on biomarker-guided sepsis management, reinforcing its commitment to the clinical education system-wide sepsis response.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the European sepsis diagnostics market employ several strategic approaches to enhance their competitive positioning. Companies focus on developing integrated diagnostic platforms that combine rapid pathogen detection, biomarker quantification, and antimicrobial resistance profiling into unified workflows. Strategic collaborations with clinical societies and national health authorities ensure alignment with sepsis guidelines and reimbursement pathways. Investment in artificial intelligence and interoperable software enables real-time clinical decision support and electronic health record integration. Expansion of point-of-care offerings addresses the need for early diagnosis in emergency and community settings. Additionally, firms prioritize regulatory compliance under the EU In Vitro Diagnostic Regulation through robust clinical validation and post-market surveillance. These strategies collectively drive clinical adoption, technological leadership,p and sustainable market presence.

MARKET SEGMENTATION

This research report has segmented and sub-segmented the europe sepsis diagnostics market into the following categories.

By Pathogen

• Bacterial Sepsis

  • Gram-Negative Bacterial Sepsis
  • Gram-Positive Bacterial Sepsis
• Fungal Sepsis
• Other Pathogen Infections

By Product

• Instruments
• Blood Culture Media
• Assay Kits & Reagents
• Software

By Technology

• Microbiology
• Molecular Diagnostics
• Immunoassays
• Flow Cytometry
• Other Technologies

By Method

• Conventional Diagnostics
• Automated Diagnostics

By Usability

• Laboratory Testing
• Point-of-Care Testing

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe